VFIC
SPRY icon

Valley Forge Investment Consultants’s ARS Pharmaceuticals SPRY Stock Holding History

Valley Forge Investment Consultants’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$667K Hold
83,225
– – 0.17% 43
2026
Q1 		$668K Hold
83,225
– – 0.2% 39
2025
Q4 		$970K Hold
83,225
– – 0.28% 31
2025
Q3 		$836K Hold
83,225
– – 0.24% 35
2025
Q2 		$1.45M Hold
83,225
– – 0.47% 23
2025
Q1 		$1.05M Hold
83,225
– – 0.37% 26
2024
Q4 		$878K Hold
83,225
– – 0.3% 34
2024
Q3 		$1.21M Buy
+83,225
New +$990K 0.42% 24

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Valley Forge Investment Consultants's SPRY Position: Q2 2026 in Review

Valley Forge Investment Consultants held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 83,225 shares worth $667K. The position accounts for 0.17% of the portfolio, ranked #43.

Valley Forge Investment Consultants first reported a position in SPRY in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.45M in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Valley Forge Investment Consultants held 83,225 shares of ARS Pharmaceuticals worth $667K as of Q2 2026.
  • Valley Forge Investment Consultants left its ARS Pharmaceuticals share count unchanged in Q2 2026.
  • ARS Pharmaceuticals made up 0.17% of Valley Forge Investment Consultants's portfolio in Q2 2026, its #43 holding.
  • Valley Forge Investment Consultants first reported a position in ARS Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Valley Forge Investment Consultants's ARS Pharmaceuticals position peaked at $1.45M in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Valley Forge Investment Consultants's 13F filing for Q2 2026, filed 7 Aug 2026.